Prosensa Announces 3rd Quarter 2014 Financial Results and Recent Corporate Developments

Recently Prosensa provided reports on their financial results for the third quarter ending September 30, 2014 as well as an update on the regulatory plans and re-dosing for drisapersen, our lead exon-skipping drug candidate, and next steps for our follow-on exon skipping compounds for the treatment of Duchenne muscular dystrophy (DMD).  Read the article on Yahoo Finance News.